Exclusive agreement with Q Biomed for future glaucoma treatment

Figure 3 from Ban et al, JCI insight, 2017,

Researchers from the Department of Ophthalmology & Visual Sciences have signed an exclusive option agreement with Q BioMed. Under the agreement granting the exclusive right to license the technology, Q BioMed will evaluate the feasibility and usability of GDF-15, a novel biomarker for monitoring glaucoma, as a companion diagnostic to the MAN-01 small molecule currently being optimized for the topical treatment of glaucoma.

This role of GDF-15 in glaucoma was recently published from our department.

For further information see the company’s press release

The publication is available to read on PubMed Central